S&P 500   3,831.42 (+0.31%)
DOW   31,387.64 (+0.38%)
QQQ   310.46 (+0.42%)
AAPL   122.33 (+0.22%)
MSFT   231.10 (+1.56%)
FB   264.56 (+3.58%)
GOOGL   2,054.71 (+2.15%)
TSLA   643.88 (-1.43%)
AMZN   3,046.00 (+1.36%)
NVDA   507.14 (-0.99%)
BABA   233.96 (-0.98%)
CGC   31.61 (-4.90%)
GE   13.59 (+1.12%)
MU   86.78 (-2.61%)
NIO   40.54 (-2.38%)
AMD   80.17 (-0.85%)
T   28.96 (+0.84%)
F   12.13 (-0.33%)
ACB   10.00 (-4.40%)
DIS   189.82 (-1.27%)
BA   229.65 (+0.48%)
NFLX   527.15 (+1.24%)
PFE   34.80 (+1.19%)
S&P 500   3,831.42 (+0.31%)
DOW   31,387.64 (+0.38%)
QQQ   310.46 (+0.42%)
AAPL   122.33 (+0.22%)
MSFT   231.10 (+1.56%)
FB   264.56 (+3.58%)
GOOGL   2,054.71 (+2.15%)
TSLA   643.88 (-1.43%)
AMZN   3,046.00 (+1.36%)
NVDA   507.14 (-0.99%)
BABA   233.96 (-0.98%)
CGC   31.61 (-4.90%)
GE   13.59 (+1.12%)
MU   86.78 (-2.61%)
NIO   40.54 (-2.38%)
AMD   80.17 (-0.85%)
T   28.96 (+0.84%)
F   12.13 (-0.33%)
ACB   10.00 (-4.40%)
DIS   189.82 (-1.27%)
BA   229.65 (+0.48%)
NFLX   527.15 (+1.24%)
PFE   34.80 (+1.19%)
S&P 500   3,831.42 (+0.31%)
DOW   31,387.64 (+0.38%)
QQQ   310.46 (+0.42%)
AAPL   122.33 (+0.22%)
MSFT   231.10 (+1.56%)
FB   264.56 (+3.58%)
GOOGL   2,054.71 (+2.15%)
TSLA   643.88 (-1.43%)
AMZN   3,046.00 (+1.36%)
NVDA   507.14 (-0.99%)
BABA   233.96 (-0.98%)
CGC   31.61 (-4.90%)
GE   13.59 (+1.12%)
MU   86.78 (-2.61%)
NIO   40.54 (-2.38%)
AMD   80.17 (-0.85%)
T   28.96 (+0.84%)
F   12.13 (-0.33%)
ACB   10.00 (-4.40%)
DIS   189.82 (-1.27%)
BA   229.65 (+0.48%)
NFLX   527.15 (+1.24%)
PFE   34.80 (+1.19%)
S&P 500   3,831.42 (+0.31%)
DOW   31,387.64 (+0.38%)
QQQ   310.46 (+0.42%)
AAPL   122.33 (+0.22%)
MSFT   231.10 (+1.56%)
FB   264.56 (+3.58%)
GOOGL   2,054.71 (+2.15%)
TSLA   643.88 (-1.43%)
AMZN   3,046.00 (+1.36%)
NVDA   507.14 (-0.99%)
BABA   233.96 (-0.98%)
CGC   31.61 (-4.90%)
GE   13.59 (+1.12%)
MU   86.78 (-2.61%)
NIO   40.54 (-2.38%)
AMD   80.17 (-0.85%)
T   28.96 (+0.84%)
F   12.13 (-0.33%)
ACB   10.00 (-4.40%)
DIS   189.82 (-1.27%)
BA   229.65 (+0.48%)
NFLX   527.15 (+1.24%)
PFE   34.80 (+1.19%)
Log in
OTCMKTS:MYMX

Mymetics Stock Forecast, Price & News

$0.10
+0.00 (+2.42 %)
(As of 03/3/2021 03:59 PM ET)
Add
Compare
Today's Range
$0.09
Now: $0.10▼
$0.10
50-Day Range
$0.07
MA: $0.10▼
$0.16
52-Week Range
$0.02
Now: $0.10▼
$0.19
Volume293,171 shs
Average Volume476,927 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta-0.08
Mymetics Corporation, a vaccine company, focuses on research and developing vaccines for infectious diseases in Switzerland. The company's product pipeline includes vaccine candidates, such as HIV-1/AIDS, intra nasal influenza, malaria, and chikungunya. It has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative; the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; RSV Corporation for developing the RSV vaccine; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.

Headlines

Mymetics secures Swiss grant to advance virosome-based COVID-19 vaccine
November 18, 2020 |  seekingalpha.com
Mymetics to Advance Preclinical Studies for Virosome-based COVID-19 Vaccine through Innosuisse Grant
November 18, 2020 |  finance.yahoo.com
Mymetics Corporation: Mymetics Starts Second Preclinical Study for Virosome-based Covid-19 Vaccine
November 2, 2020 |  finanznachrichten.de
Mymetics Starts Second Preclinical Study for Virosome-based Covid-19 Vaccine
November 2, 2020 |  finance.yahoo.com
Mymetics Corporation: Mymetics Starts Preclinical Studies with Baylor College of Medicine for Virosome-based Covid-19 Vaccine
September 23, 2020 |  finanznachrichten.de
Mymetics Starts Preclinical Studies with Baylor College of Medicine for Virosome-based Covid-19 Vaccine
September 23, 2020 |  finance.yahoo.com
Mymetics nabs European support for virosome-based COVID-19 vaccine
June 11, 2020 |  seekingalpha.com
Mymetics Receives Support for Virosome-based Covid-19 Vaccine Development from European Vaccine Infrastructure Project (Transvac2)
June 11, 2020 |  finance.yahoo.com
Mymetics Reports Successful Preclinical Study Results with COP-Virosomes as Second-Generation Allergy Immunotherapy
May 28, 2020 |  finance.yahoo.com
Mymetics and Baylor College of Medicine ink deal for COVID-19 vaccines
May 18, 2020 |  seekingalpha.com
Mymetics and Baylor College of Medicine start Research Collaboration for Virosome-based Covid-19 Vaccines
May 18, 2020 |  finance.yahoo.com
Mymetics Corp.
April 25, 2020 |  www.marketwatch.com
Mymetics Corporation: Mymetics Announces New Study to Predict Efficacy of Second- Generation COP Allergy Immunotherpy with Virosomes
October 18, 2019 |  www.finanznachrichten.de
Mymetics Announces New Study to Predict Efficacy of Second- Generation COP Allergy Immunotherpy with Virosomes
October 17, 2019 |  finance.yahoo.com
MYM Closes $5.5 Million Financing With Trichome Financial Corp.
August 1, 2019 |  finance.yahoo.com
Mymetics Corporation: Mymetics Receives Funding from NIH for Novel HIV Vaccine Study
April 29, 2019 |  www.finanznachrichten.de
Mymetics Receives Funding from NIH for Novel HIV Vaccine Study
April 29, 2019 |  finance.yahoo.com
Mymetics receives HIV Vaccine Funding from the NIH
April 29, 2019 |  finance.yahoo.com
Mymetics Corp
March 19, 2019 |  www.bloomberg.com
Mymetics Virosomes Successful in Allergy Proof-of-Concept Study
December 13, 2018 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MYMX
Previous Symbol
CUSIPN/A
CIK927761
Webwww.mymetics.com
Phone41-21-653-4535
Employees9
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio0.01
Quick Ratio0.01

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$730,000.00
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-4,690,000.00
Net Margins-909.49%
Return on EquityN/A
Return on Assets-52.68%

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings Date3/29/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

0.63 out of 5 stars

Medical Sector

1311th out of 1,968 stocks

Biological Products, Except Diagnostic Industry

152nd out of 177 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$0.10
+0.00 (+2.42 %)
(As of 03/3/2021 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MYMX News and Ratings via Email

Sign-up to receive the latest news and ratings for MYMX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mymetics (OTCMKTS:MYMX) Frequently Asked Questions

What stocks does MarketBeat like better than Mymetics?

Wall Street analysts have given Mymetics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mymetics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Mymetics?

Mymetics saw a decrease in short interest in the month of February. As of February 12th, there was short interest totaling 2,600 shares, a decrease of 96.3% from the January 28th total of 70,800 shares. Based on an average daily trading volume, of 1,295,900 shares, the short-interest ratio is presently 0.0 days.
View Mymetics' Short Interest.

When is Mymetics' next earnings date?

Mymetics is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for Mymetics.

How has Mymetics' stock price been impacted by Coronavirus?

Mymetics' stock was trading at $0.0379 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MYMX stock has increased by 168.1% and is now trading at $0.1016.
View which stocks have been most impacted by COVID-19.

Who are Mymetics' key executives?

Mymetics' management team includes the following people:
  • Mr. Ronald Kempers, CEO, Pres & CFO (Age 53)
  • Dr. Sylvain Fleury, Chief Scientific Officer (Age 59)
  • Dr. Antonius Johanne Stegmann, Head of R&D and Chief Scientific Officer of Mymetics BV
  • Mr. Mario Amacker Ph.D., Head of Quality & Manufacturing

Who are some of Mymetics' key competitors?

Some companies that are related to Mymetics include AVAX Technologies (AVXT), Cornwall Resources (CORC), Neurobiological Technologies (NTII), Omni Bio Pharmaceutical (OMBP), Panacos Pharmaceuticals (PANC), Protide Pharmaceuticals (PPMD), Tengion (TNGNQ) and VIA Pharmaceuticals (VIAP).
View all of MYMX's competitors.

What other stocks do shareholders of Mymetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mymetics investors own include Genocea Biosciences (GNCA), Dynavax Technologies (DVAX), Fujitsu (FJTSY), Himax Technologies (HIMX), Maxar Technologies (MAXR), Revance Therapeutics (RVNC), The Boeing (BA), Activision Blizzard (ATVI), Asure Software (ASUR) and Arlo Technologies (ARLO).

What is Mymetics' stock symbol?

Mymetics trades on the OTCMKTS under the ticker symbol "MYMX."

How do I buy shares of Mymetics?

Shares of MYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mymetics' stock price today?

One share of MYMX stock can currently be purchased for approximately $0.10.

How many employees does Mymetics have?

Mymetics employs 9 workers across the globe.

What is Mymetics' official website?

The official website for Mymetics is www.mymetics.com.

Where are Mymetics' headquarters?

Mymetics is headquartered at Route de la Corniche 4, Epalinges V8, CH-1066.

How can I contact Mymetics?

Mymetics' mailing address is Route de la Corniche 4, Epalinges V8, CH-1066. The company can be reached via phone at 41-21-653-4535 or via email at [email protected]


This page was last updated on 3/4/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.